Jorge Santos da Silva - 09 Jul 2026 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: MLTX
Reported as of: 09 Jul 2026
Net transaction value: -$2,046,205
SEC form: 4
Accepted by SEC: 13 Jul 2026, 16:10:17 UTC
Prior SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthias Bodenstedt, Attorney-in-fact for Jorge Santos da Silva

Key filing fact

Jorge Santos da Silva filed Form 4 for MoonLake Immunotherapeutics (MLTX) on 13 Jul 2026.

Key facts

This page summarizes Jorge Santos da Silva's Form 4 filing for MoonLake Immunotherapeutics (MLTX).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 13 Jul 2026, 16:10.

Change

Previous filing in this sequence was filed on 02 Jul 2026.
Current net transaction value: -$2,046,205.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001920509 Primary reporting owner

Santos da Silva Jorge

Relationship: Chief Executive Officer, Director
Address: C/O MOONLAKE IMMUNOTHERAPEUTICS, DORFSTRASSE 29, ZUG, SWITZERLAND
Signature: /s/ Matthias Bodenstedt, Attorney-in-fact for Jorge Santos da Silva
Signature date: 13 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MLTX transaction

Class A ordinary shares, par value $0.0001 per share

Sale

Transaction value: $679,059
Shares: -33,936
Change %: -1.2%
Price: $20.01
Shares after: 2,843,182
Date: 09 Jul 2026
Ownership: Direct
Footnotes: F1, F2

MLTX transaction

Class A ordinary shares, par value $0.0001 per share

Sale

Transaction value: $1,367,146
Shares: -68,289
Change %: -2.4%
Price: $20.02
Shares after: 2,774,893
Date: 10 Jul 2026
Ownership: Direct
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

Footnote F2

The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.03. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Footnote F3

The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.10. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.